CTIC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CTIC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
CTI BioPharma's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.00 Mil.
CTI BioPharma's quarterly Long-Term Capital Lease Obligation declined from Sep. 2022 ($1.44 Mil) to Dec. 2022 ($1.23 Mil) and declined from Dec. 2022 ($1.23 Mil) to Mar. 2023 ($0.00 Mil).
CTI BioPharma's annual Long-Term Capital Lease Obligation increased from Dec. 2020 ($0.00 Mil) to Dec. 2021 ($2.02 Mil) but then declined from Dec. 2021 ($2.02 Mil) to Dec. 2022 ($1.23 Mil).
The historical data trend for CTI BioPharma's Long-Term Capital Lease Obligation can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTI BioPharma Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Long-Term Capital Lease Obligation | Get a 7-Day Free Trial | - | 2.99 | - | 2.02 | 1.23 |
CTI BioPharma Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
Long-Term Capital Lease Obligation | Get a 7-Day Free Trial | - | 1.64 | 1.44 | 1.23 | - |
CTI BioPharma (NAS:CTIC) Long-Term Capital Lease Obligation Explanation
Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.
Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:
1. Ownership of the asset is transferred to the lessee at the end of the lease term;Thank you for viewing the detailed overview of CTI BioPharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.
James K Fong | officer: EVP & Chief Commercial Officer | C/O CTI BIOPHARMA CORP, 3101 WESTERN AVENUE, SUITE 800, SEATTLE WA 98121 |
Adam R Craig | director, officer: President and CEO | C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
David Kirske | officer: EVP, Chief Financial Officer | C/O CTI BIOPHARMA CORP., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Michael A Metzger | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Diane L. Parks | director | 29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540 |
Matthew D Perry | director | ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104 |
Orbimed Advisors Llc | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Bvf I Gp Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Gp Holdings Llc | 10 percent owner | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Bvf Ii Gp Llc | other: See Explanation of Responses | 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Laurent Fischer | director | C/O ADVERUM BIOTECHNOLOGIES, INC., 100 CARDINAL WAY, REDWOOD CITY CA 94063 |
David Ross Parkinson | director | C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Richard L Love | director | |
Biotechnology Value Fund Ii Lp | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
From GuruFocus
By PRNewswire PRNewswire • 05-23-2023
By PRNewswire PRNewswire • 02-23-2023
By sperokesalga sperokesalga • 05-11-2023
By PRNewswire PRNewswire • 06-07-2023
By Business Wire Business Wire • 05-10-2023
By PRNewswire PRNewswire • 05-10-2023
By PRNewswire PRNewswire • 03-21-2023
By PRNewswire PRNewswire • 05-05-2023
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire PRNewswire • 01-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.